Vivos Therapeutics has released new patient management software for diagnosing, treating, and monitoring patients with obstructive sleep apnea.
AireO2 will help medical and dental health providers manage caseloads and increase the number of patients they can treat, according to Vivos Therapeutics. The company developed the software in collaboration with Lyon Dental; it includes billing and practice management features, Vivos said.
Obstructive sleep apnea is one of the most prevalent diseases in the world. If untreated, it can boost patients' risk of comorbidities such as high blood pressure, heart failure, and stroke, according to the firm.